This week on Careers in Discovery, we are joined by Peter Pack, an influential figure in the biotechnology industry with a career spanning over two decades.

Peter's journey has taken him from Germany to the dynamic biotech landscape of the UK, where he now operates as a strategic partner and advisor to private equity firms and startups.

In our conversation, Peter shares his diverse experiences, including his time as a CEO for nearly 20 years and his current role mentoring young biotech teams. He offers insights into the differences between the biotech industries in Germany and the UK, the importance of building strong networks, and his passion for supporting innovative startups.

Peter also reflects on his early inspirations in science, the development of groundbreaking technologies at Morphosys, and the valuable lessons he has learned about commercialization and strategic decision-making. He emphasizes the importance of collaboration, learning from mistakes, and the critical role of supportive investors.

Join us as we explore Peter's fascinating career, his views on the future of biotech, and the key factors that contribute to successful leadership in this ever-evolving field.

Don't miss this episode full of insights from a biotech veteran who continues to shape the industry.

"Science and technology have always fascinated me, and I've always been one to challenge the status quo."

This week on Careers in Discovery, we welcome Jose Munoz-Olaya, Chief Scientific Officer of Valink Therapeutics.

Jose shares his journey from an eager intern to a leader in biotechnology, emphasizing the importance of mentorship and the power of teamwork. He discusses his role at Valink, where he's spearheading the development of next-generation Antibody-Drug Conjugates (ADCs) for oncology using their innovative high-throughput screening platform.

Join us as Jose discusses:

• His early inspiration from a high school science teacher and his diverse family background

Tune in for all this, and much more....

Mike Stubbington and CS Genetics are on a mission to democratise single cell genomics. We caught up with Mike recently and discussed what being kind really looks like as a scientist, why you should move on when the time is right, and a whole lot more.

We first interviewed Ben Cross five years ago, when he was the Head of Functional Genomics at Horizon Discovery, and we're delighted to welcome him back to the podcast as CTO of PhoreMost, an innovative target discovery company focused on drugging the undruggable.

Ben caught us up on what he's learned over the last five years, including why failing fast isn't a viable strategy in drug discovery, and introduced us to PhoreMost's brand new molecular glue platform, GlueSeeker.

Shane Hegarty is the Chief Scientific Officer of Axonis Therapeutics, a Boston-based Biotech targeting KCC2 to revive neurons and treat people suffering from neurological disorders.

Shane shared with us the story of his transition from academic to Biotech entrepreneur, why communication, persistence, collaboration and focus are critical skills for success, his amazing track record of securing grant funding, and much more.

Maude Tessier is the Chief Business Officer at Seismic Therapeutic, the machine learning immunology company building a discovery platform centred on parallel drug development.

Maude joined us on Careers in Discovery to talk about the impact of machine learning on drug development, taking control of her career by literally knocking on doors, balancing humility and confidence, and much more.

Vern de Biasi is VP of Business Development at BenevolentAI, one of the world's leaders in the application of cutting edge technology to drug discovery.

Vern's career has seen him travel the world, from the UK to Italy, China and the US, and he shared with us the key lessons he's learned along the way.

Jordan Lane is the Chief Scientific Officer of Ignota Labs, a company leveraging AI to rescue failed drug programmes.

Jordan joined us to talk about building conviction, seeking feedback & maintaining networks, the huge opportunity lying in failed research, and why risk is relative in your career.

Bill Eldridge is an experienced scientific and commercial leader, one of the founding team members of the VHH antibody company Isogenica, and now their CEO.

Bill joined us to talk about his career, the huge potential that still exists within antibody discovery and the magic of seeing a 96 well ELISA plate turn blue after months of failure!

Enjoy...

Namir Hassan is the CEO of Zelluna Immunotherapy, a cancer cell therapy company harnessing natural immunity to treat solid tumours.

Namir joined us on Careers in Discovery to talk about when precision medicine gets too precise, the importance of servant leadership and trusting the journey in your career.

Enjoy!